UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.40 Million Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of RxSight, Inc. (NASDAQ:RXST) by 8.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,818 shares of the company’s stock after acquiring an additional 5,266 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.17% of RxSight worth $3,402,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in RXST. Algert Global LLC bought a new position in RxSight during the 2nd quarter valued at about $2,488,000. Victory Capital Management Inc. grew its stake in RxSight by 21.0% during the third quarter. Victory Capital Management Inc. now owns 259,864 shares of the company’s stock worth $12,845,000 after buying an additional 45,161 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of RxSight by 17.0% during the second quarter. Bank of New York Mellon Corp now owns 119,493 shares of the company’s stock worth $7,190,000 after buying an additional 17,368 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of RxSight by 17.0% in the third quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock valued at $20,711,000 after acquiring an additional 60,789 shares during the last quarter. Finally, Legato Capital Management LLC boosted its holdings in shares of RxSight by 46.7% in the 2nd quarter. Legato Capital Management LLC now owns 29,800 shares of the company’s stock worth $1,793,000 after acquiring an additional 9,486 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Price Performance

RXST opened at $37.30 on Friday. The company has a market capitalization of $1.50 billion, a PE ratio of -44.94 and a beta of 1.11. The business has a fifty day simple moving average of $46.98 and a 200 day simple moving average of $50.86. RxSight, Inc. has a 1 year low of $34.92 and a 1 year high of $66.54.

Wall Street Analysts Forecast Growth

RXST has been the subject of a number of research reports. Jefferies Financial Group started coverage on RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. UBS Group began coverage on shares of RxSight in a research note on Friday, December 6th. They issued a “buy” rating and a $52.00 target price for the company. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $42.00 price target (down from $56.00) on shares of RxSight in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $62.13.

Insider Buying and Selling at RxSight

In other RxSight news, Director Jesse Anderson Corley acquired 11,111 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the transaction, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. This represents a 2.43 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ilya Goldshleger sold 3,105 shares of RxSight stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $46.08, for a total transaction of $143,078.40. Following the sale, the insider now directly owns 42,246 shares in the company, valued at $1,946,695.68. This trade represents a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 65,807 shares of company stock valued at $3,202,275 in the last quarter. Company insiders own 9.36% of the company’s stock.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.